← Eichor
Condition: Alagille Syndrome Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Alagille Syndrome

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahe
Phase N/A · 1 location(s) · Takeda · NCT07293897A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALG
Phase N/A · 10 location(s) · Ipsen · NCT06850038Pediatric Evaluation and Registry for Liver Cholestasis in Canada
Phase N/A · 13 location(s) · Children's Hospital of Eastern Ontario · NCT07411716Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai)
Phase N/A · 1 location(s) · Asociación Española para el Estudio del Hígado · NCT06767605Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome o
Phase 4 · 15 location(s) · Mirum Pharmaceuticals, Inc. · NCT07290257Dental Dyschromia and Quality of Life in Early Prolonged Hyperbilirubinemia
Phase N/A · 9 location(s) · University Hospital, Toulouse · NCT06506734Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
Phase N/A · 8 location(s) · Mirum Pharmaceuticals, Inc. · NCT06193928
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.